PharmaExec Consulting AB

PharmaExec Consulting AB discloses dealings in Egetis Therapeutics AB (publ) to Finansinspektionen. Between 20 May 2021 and 17 May 2022, the trades on record add up to 4 filings.

Purchases make up the whole of the open-market record (3 purchases, €107k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 1 share grant.

In size, the median ticket on the buying side is €48k. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 20 May 2022 came the latest disclosure, a share grant for €24k in Egetis Therapeutics AB (publ). The most recent open-market purchase was published on 24 May 2021, 1,995 days ago. Filings reach the Finansinspektionen feed a median of 1 day after the trade. The regulation allows three business days to notify a trade (MAR article 19). These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.